Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression

Berlanga‐Acosta, Jorge; Gavilondo-Cowley, Jorge; Barco-Herrera, Diana García del; Martín-Machado, Jorge; Guillén-Nieto, Gerardo

doi:10.4172/2157-2518.1000115

Cited by 25 publications

(24 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, vast amounts of data have been gathered about applications of hEGF in treating a wide variety of wounds through various routes of administration [15]. Interestingly, despite the reports of numerous successful treatments in these studies, none of them has offered significant evidence to support that exogenous introduction of hEGF would promote carcinogenesis [15,16]. On the other hand, mutants of EGF receptor, which are able to undertake ligand-independent gene activation and possess increased ligand affinity, have been speculated to be a cause of malignant transformation [16].…”

Section: Resultsmentioning

confidence: 99%

“…Interestingly, despite the reports of numerous successful treatments in these studies, none of them has offered significant evidence to support that exogenous introduction of hEGF would promote carcinogenesis [15,16]. On the other hand, mutants of EGF receptor, which are able to undertake ligand-independent gene activation and possess increased ligand affinity, have been speculated to be a cause of malignant transformation [16]. In yet another direction, it may be interesting to investigate the ability of different forms of hEGF, including authentic hEGF and its Figure 1).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effective Treatment of an Unhealed Incision of a Diabetic Patient with Recombinant Human Epidermal Growth Factor

Wong¹

2015

Mod Chem Appl

View full text Add to dashboard Cite

A facile protocol, which involves topical application of recombinant human Epidermal Growth Factor (rhEGF), was previously developed by our group and shown to be effective in treating diabetic foot ulcers, when working in conjunction with debridement surgery. In this communication, using the same approach of rhEGF application, despite the absence of debridement, our findings demonstrated that the protocol worked equally well on a hard-to-heal wound, which remained unhealed subsequent to surgical removal of the great saphenous vein from the left thigh of a diabetic patient. After treatment with rhEGF for 10 d, the wound was shown to heal readily and finally achieved complete healing. The success of rhEGF in the healing process is concluded to be attributable to both the fine quality and sufficient dosage of rhEGF.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Effective Treatment of an Unhealed Incision of a Diabetic Patient with Recombinant Human Epidermal Growth Factor

Wong¹

2015

Mod Chem Appl

View full text Add to dashboard Cite

show abstract

“…Contrary to PDGF, EGF cannot initiate malignant transformation [55]. However, the promotion of a pre-existing tumor, clinically evident or not, is potentially possible.…”

Section: Can Parentally Administered Rhegf Stimulate Tumor Growth?mentioning

confidence: 99%

Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers

Yera-Alos¹

2013

Adv Pharmacoepidem Drug Safety

View full text Add to dashboard Cite

“…Autocrine loops involving the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), or insulin-like growth factor receptor (IGFR) have been described in many cancers [9–14]. Increased expression of EGFR is reported in many human cancers including non-small cell lung cancer, bladder cancer, breast cancer and glioblastoma multiforme [2].…”

Section: Introductionmentioning

confidence: 99%

Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells

Lasota¹,

Klein²,

Balwierz³

2012

View full text Add to dashboard Cite

Aim of the studyThe aim of the work was to determine the influence of tyrphostin AG1296, an inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine kinase, on autocrine growth of rhabdomyosarcoma (RMS) cells.Materials and methodsRMS cells were cultured in serum-free DMEM/F12 medium. Modified crystal violet (CV) and MTT methods were used to determine the RMS cells’ proliferation and viability. Influence of the investigated inhibitor on cell apoptosis or necrosis was determined by differential staining with Hoechst No. 33258 and propidium iodide.ResultsThe AG1296 inhibitor affects RMS cell proliferation in a dose-dependent way at the concentration range 1–100 µM. At concentrations above 25 µM there was 100% inhibition of growth of these cells and a cytotoxic effect was noticed. 50% inhibition of RMS cells proliferation (IC50) was observed at concentration 6.65 ±0.44 µM (determined by CV method) and 7.30 ±0.26 µM (determined by MTT method). The differential staining method shows that this inhibitor causes a cytotoxic effect.ConclusionThe results of these experiments indicate that autocrine growth of RMS cells is regulated by at least one autocrine loop, involving platelet-derived growth factor (PDGF) and its receptor (PDGFR).The fact that tyrphostin AG1296 is able to complete inhibition of RMS cell growth in vitro gives a chance for providing a new group of antitumor drugs, which may be more effective than the medicines used so far.

show abstract

Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression

Cited by 25 publications

References 132 publications

Effective Treatment of an Unhealed Incision of a Diabetic Patient with Recombinant Human Epidermal Growth Factor

Effective Treatment of an Unhealed Incision of a Diabetic Patient with Recombinant Human Epidermal Growth Factor

Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers

Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells

Contact Info

Product

Resources

About